Trisalus Life Sciences, Inc. current report, 14 November 2022

Full document

SEC Form 8-K Summary

Registrant: MedTech Acquisition Corporation (MTAC), which expects to be renamed TriSalus Life Sciences, Inc. upon completion of the proposed business combination.

Report date: November 14, 2022. The filing reports events occurring on November 11, 2022. It is primarily a Regulation FD disclosure and does not present a quarterly or annual reporting period.

Business Context and Transaction

MTAC entered into an Agreement and Plan of Merger with MTAC Merger Sub, Inc. and TriSalus Life Sciences, Inc. Under the proposed transaction, Merger Sub would merge with TriSalus, with TriSalus surviving as a wholly owned subsidiary of MTAC. TriSalus equity holders would receive MTAC common stock.

Upon closing, MTAC would be renamed TriSalus Life Sciences, Inc. The filing includes investor, employee, customer, supplier, business partner, government officer and regulator communications as exhibits.

Financial Metrics and Liquidity

  • The filing does not provide clear figures for revenue, profit or loss, operating cash flow, margins, debt, cash balances, liquidity or other operating metrics.
  • The filing states that financial information included in the current report is unaudited, preliminary and not compliant with Regulation S-X.
  • TriSalus financial information may be adjusted or presented differently in the future Form S-4, and differences could be material.
  • The amount of cash expected to be delivered from MTAC’s trust account and any additional financing remain subject to transaction conditions, including shareholder redemptions and minimum-cash requirements.

Material Changes Versus Prior Period

The material development is the execution of the proposed merger agreement. The filing does not provide comparative financial statements or quantify changes from a prior comparable period.

Outlook, Conditions and Risks

MTAC intends to file a Form S-4 registration statement containing a proxy statement/prospectus. The registration statement was not yet effective as of the filing date. MTAC stockholders will be asked to approve the business combination at a future special meeting.

  • Completion depends on shareholder approval, satisfaction of the minimum-cash condition after redemptions, applicable governmental and regulatory approvals, including reimbursement approval, and other customary closing conditions.
  • The transaction may not close by MTAC’s business-combination deadline, and an extension may not be obtained.
  • Key business risks include reimbursement changes, clinical or regulatory failure, inability to obtain approvals, inability to grow TriNav sales, market adoption, competition, funding needs, additional financing, and execution of growth plans.
  • Other risks include transaction termination, competing offers, litigation, Nasdaq listing risks, disruption to TriSalus’s operations and relationships, transaction costs and failure to realize projected benefits or pro forma results.
  • Forward-looking statements regarding market size, product adoption, regulatory approval, projected financial results, valuation, financing and shareholder value are subject to substantial uncertainty.

Important Facts to Verify

  • Review the eventual Form S-4 and proxy statement/prospectus for audited financial statements, pro forma results, valuation, capitalization, transaction consideration and risk factors.
  • Verify the amount of cash remaining in MTAC’s trust account, expected shareholder redemptions, minimum-cash compliance and any committed financing.
  • Confirm required MTAC shareholder, governmental, regulatory and reimbursement approvals and the applicable business-combination deadline.
  • Assess TriSalus’s revenue trends, TriNav sales, cash burn, debt, clinical pipeline, reimbursement status and funding requirements using subsequent SEC filings.
  • Review the merger agreement for termination rights, closing conditions, transaction expenses, dilution and protections for public shareholders.
  • Note that the communications furnished as exhibits are not deemed filed under Section 18 of the Exchange Act, and the filing does not constitute an offer or solicitation of securities.